Two Yale faculty members, Donald Engelman and Debra Fischer, have been named fellows of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society.
Engelman is the Eugene Higgins Professor of Molecular...
A new, Yale-led analysis suggests that the Coca-Cola Company and a number of other corporations are the real thing when it comes to publicly reporting the environmental impact of their operations — something the American health care industry would do well...
A new study suggests that a contributing factor in dementia may come down to a double dose of bad waste management in the brain.
A research team led by Yale, Stony Brook University, and the University of Rhode Island found that the body’s systems for...
A new study shows that one in three patients with a severe skin disease were able to regrow hair after being treated with a common arthritis drug.
The study is based on Phase 3 clinical trials using baricitinib, a Janus kinase (JAK) inhibitor, to treat...
In a new study, Yale researchers take a unique approach to identify the molecular signals that induce a critical trigger for hair follicle formation and regeneration.
The findings could prove crucial for developing new therapies to re-grow hair — and...
Dr. Brett King, associate professor of dermatology at Yale School of Medicine, has been named an American Academy of Dermatology (AAD) “Patient Care Hero” for his pioneering work treating conditions such as severe alopecia.
AAD cited King’s innovative use...
A new study by investigators at the Yale Center for Outcomes Research and Evaluation (CORE) and Harvard shows the Omicron variant of the COVID-19 virus caused more excess deaths in just eight weeks than the Delta variant caused in its entire 23-week...
In a June 13 announcement, the U.S. Food and Drug Administration approved the use of the Janus kinase (JAK) inhibitor baricitinib as a treatment for severe alopecia areata, a disfiguring skin disease.
It is the first approved treatment for alopecia areata...
Every patient in a Yale clinical trial of a new treatment for the disfiguring disease sarcoidosis saw improvement to their skin — and more than half showed improvement in affected internal organs.
Sarcoidosis is a disease affecting four out of every 10,...
Yale researchers have developed a new class of molecules that target some of the deadliest brain cancers while sparing healthy tissue along the way.
The discovery, which combines innovative synthetic chemistry and cutting-edge mechanistic studies in...